Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/128821
Título: COVID-19 in Adults With Congenital Heart Disease
Autores/as: Broberg, CS
Kovacs, AH
Sadeghi, S
Rosenbaum, MS
Lewis, MJ
Carazo, MR
Rodriguez, FH
Halpern, DG
Feinberg, J
Galilea, FA
Baraona, F
Cedars, AM
Ko, JM
Porayette, P
Maldonado, J
Sarubbi, B
Fusco, F
Frogoudaki, AA
Nir, A
Chaudhry, A
John, AS
Karbassi, A
Hoskoppal, AK
Frischhertz, BP
Hendrickson, B
Bouma, BJ
Rodriguez-Monserrate, CP
Broda, CR
Tobler, D
Gregg, D
Martínez Quintana, Efrén 
Yeung, E
Krieger, EV
Ruperti-Repilado, FJ
Giannakoulas, G
Lui, GK
Ephrem, G
Singh, HS
Almeneisi, HMK
Bartlett, HL
Lindsay, I
Grewal, J
Nicolarsen, J
Araujo, JJ
Cramer, JW
Bouchardy, J
Al Najashi, K
Ryan, K
Alshawabkeh, L
Andrade, L
Ladouceur, M
Schwerzmann, M
Greutmann, M
Meras, P
Ferrero, P
Dehghani, P
Tung, PP
Garcia-Orta, R
Tompkins, RO
Gendi, SM
Cohen, S
Klewer, S
Hascoet, S
Mohammadzadeh, S
Upadhyay, S
Fisher, SD
Cook, S
Cotts, TB
Aboulhosn, JA
Clasificación UNESCO: 32 Ciencias médicas
320505 Enfermedades infecciosas
Palabras clave: Adult congenital heart disease
Coronavirus
COVID-19
Hospitalization
Fecha de publicación: 2021
Publicación seriada: Journal of the American College of Cardiology 
Resumen: Background: Adults with congenital heart disease (CHD) have been considered potentially high risk for novel coronavirus disease-19 (COVID-19) mortality or other complications. Objectives: This study sought to define the impact of COVID-19 in adults with CHD and to identify risk factors associated with adverse outcomes. Methods: Adults (age 18 years or older) with CHD and with confirmed or clinically suspected COVID-19 were included from CHD centers worldwide. Data collection included anatomic diagnosis and subsequent interventions, comorbidities, medications, echocardiographic findings, presenting symptoms, course of illness, and outcomes. Predictors of death or severe infection were determined. Results: From 58 adult CHD centers, the study included 1,044 infected patients (age: 35.1 ± 13.0 years; range 18 to 86 years; 51% women), 87% of whom had laboratory-confirmed coronavirus infection. The cohort included 118 (11%) patients with single ventricle and/or Fontan physiology, 87 (8%) patients with cyanosis, and 73 (7%) patients with pulmonary hypertension. There were 24 COVID-related deaths (case/fatality: 2.3%; 95% confidence interval: 1.4% to 3.2%). Factors associated with death included male sex, diabetes, cyanosis, pulmonary hypertension, renal insufficiency, and previous hospital admission for heart failure. Worse physiological stage was associated with mortality (p = 0.001), whereas anatomic complexity or defect group were not. Conclusions: COVID-19 mortality in adults with CHD is commensurate with the general population. The most vulnerable patients are those with worse physiological stage, such as cyanosis and pulmonary hypertension, whereas anatomic complexity does not appear to predict infection severity.
URI: http://hdl.handle.net/10553/128821
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2021.02.023
Fuente: Journal of the American College of Cardiology [0735-1097], v. 77(13), p. 1644-1655 (abril 2021)
Colección:Artículos
Adobe PDF (1,29 MB)
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.